0000897069-23-001052.txt : 20230802
0000897069-23-001052.hdr.sgml : 20230802
20230802170637
ACCESSION NUMBER: 0000897069-23-001052
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230731
FILED AS OF DATE: 20230802
DATE AS OF CHANGE: 20230802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peyer James
CENTRAL INDEX KEY: 0001843594
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39980
FILM NUMBER: 231136822
MAIL ADDRESS:
STREET 1: C/O SENSEI BIOTHERAPEUTICS, INC.
STREET 2: 1405 RESEARCH BLVD., STE. 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001829802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1405 RESEARCH BLVD, SUITE 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: (240) 243-8000
MAIL ADDRESS:
STREET 1: 1405 RESEARCH BLVD, SUITE 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
form4.xml
X0508
4
2023-07-31
0001829802
Sensei Biotherapeutics, Inc.
SNSE
0001843594
Peyer James
228 PARK AVENUE S. #66643
NEW YORK
NY
10003
true
true
false
Common Stock
2023-07-31
4
D
0
1587302
1.26
D
3653120
I
See footnote
Shares purchased by the Issuer pursuant to a Purchase Agreement, dated July 31, 2023, by and among the Issuer, the Reporting Person and Cambrian BioPharma Inc. This transaction, which was approved by the Board of Directors of the Issuer, is exempt pursuant to Rule 16b-3(e) of the Securities Exchange Act of 1934, as amended.
These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
/s/ James Peyer
2023-08-02